Aminopyridine Sustained-Release Matrix for Neurological Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders such as spinal cord injuries, multiple sclerosis, and Alzheimer's disease are limited in effectively promoting nerve impulse transmission and managing symptoms, with existing medications often causing adverse side effects and having limited duration of action.
Innovation Solution
A sustained-release oral dosage form of aminopyridine, dispersed in a hydrophilic polymer matrix like hydroxypropylmethylcellulose, provides a controlled release of the potassium channel blocker, maintaining therapeutic plasma levels for extended periods while minimizing peak concentrations and adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If immediate release aminopyridine is used, then rapid nerve impulse transmission improvement is achieved, but plasma levels peak and trough rapidly causing adverse side effects and limited duration of action
Solution Approach 1:
The immediate release dosing is segmented into multiple smaller doses administered at different times throughout the day, rather than a single large dose. This segmentation flattens the plasma concentration curve, eliminating sharp peaks and troughs while maintaining continuous therapeutic effect, thereby reducing adverse side effects and extending the effective duration of action
Solution Approach 2:
The formulation is designed to release aminopyridine in a controlled, predetermined manner over an extended period. By planning the release profile in advance through formulation design (using matrices or coatings that control dissolution rates), the plasma levels are maintained within a narrow therapeutic window without sharp fluctuations, preventing both peak-related toxicity and trough-related loss of efficacy
2Reliability
If higher doses of aminopyridine are administered, then therapeutic effect is enhanced, but adverse side effects increase due to peak plasma concentrations
Solution Approach 1:
Instead of administering a single large dose, the total daily dose is divided into multiple periodic administrations throughout the day. This periodic dosing pattern maintains stable plasma concentrations by continuously replenishing the drug at a controlled rate, ensuring consistent therapeutic effect while avoiding the harmful peak concentrations that would result from intermittent large doses
Solution Approach 2:
The formulation changes the key parameter of release rate by using controlled-release matrices or coatings with specific dissolution characteristics. This parameter change transforms the plasma concentration profile from a sharp peak pattern to a flattened, sustained profile, allowing higher total daily doses to be administered without proportionally increasing peak concentrations and adverse side effects
3Stability of the object's composition
If frequent dosing is used to maintain therapeutic levels, then plasma level stability is improved, but patient convenience and compliance deteriorate
Solution Approach 1:
The dosing schedule is segmented into specific time points throughout the day, with each dose contributing to a cumulative stable plasma level. By segmenting the total daily dose into multiple smaller, timed administrations, the formulation achieves plasma level stability without requiring continuous dosing, making it more convenient and compliant for patients
Solution Approach 2:
The formulation ensures continuous therapeutic action by designing the release profile to maintain plasma levels within the therapeutic window throughout the dosing interval. This continuity is achieved through controlled-release mechanisms that prevent premature drug exhaustion, eliminating the need for frequent dosing while maintaining stable plasma concentrations and improving patient convenience
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sustained-release formulation effectively treats neurological disorders by maintaining therapeutic levels of aminopyridine for up to 24 hours, reducing side effects and improving nerve impulse transmission, muscle strength, and reducing muscle spasticity, with a stable and uniform distribution of the drug.
Implementation Method 1
The aminopyridine dispersed in the matrix is capable of providing, upon administration to a patient, a desired release profile
Implementation Method 2
dispersed in a hydrophilic polymer matrix like hydroxypropylmethylcellulose
Data Source
AI summary
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.